We recently developed a digital cytometric assay using plasmonic nanoparticles to quantify the bound ovarian cancer marker (CA125) on single cells. We demonstrate the quantification capability of our novel digital cytometry method by discriminating the different MUC16 binding levels on the PBMCs between healthy donors and EOC patients. Furthermore, we tracked the amount of surface-bound MUC16 on the EOC patient’s PBMCs over 17 months with 1-month time intervals. Initial data from our cytometric technique shows it to be a quantitative tool that can provide new information connecting leukocyte-bound MUC16 to the time course of ovarian cancer.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.